جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

7 مُخرَج نتائج البحث عن «clinical data»

مقالوصول مفتوح20261استشهاد· Semantic Scholar

GLP-1 receptor agonists as potential disease-modifying agents in Parkinson’s and Alzheimer’s disease: mechanisms, clinical trial evidence, and the neuroprotection horizon

Frontiers in Aging Neuroscience · مجلد 18

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed as antidiabetic agents, have emerged as candidate disease-modifying therapies for Parkinson’s disease (PD) and Alzheimer’s disease (AD), reflecting the widespread expression of GLP-1 receptors across neurons, glia, and the cerebral vasculature. This narrative review synthesizes mechanistic, clinical trial, and biomarker evidence for GLP-1 RAs in PD and AD, based on a literature search of PubMed, Embase, Scopus, and Web of Science, with ClinicalTrials.gov searched separately for trial protocols and results, through May 2026. Preclinical data implicate GLP-1 receptor agonism in anti-neuroinflammatory signaling, mitochondrial preservation, autophagy and proteostasis enhancement, anti-apoptotic effects, synaptic plasticity, cerebrovascular protection, and glymphatic clearance. Clinical evidence in PD is mixed and agent- and formulation-dependent: the phase II Exenatide-PD trial reported a motor benefit that persisted after washout (∼3.5-point between-group difference in MDS-UPDRS Part III), and the phase II LIXIPARK trial (lixisenatide) reported a significant 3.08-point between-group difference (95% CI 0.86–5.30; p = 0.007) favoring lixisenatide, whereas the larger, longer phase III Exenatide-PD3 trial, using an extended-release weekly formulation, found no significant effect on the same endpoint (adjusted coefficient 0.92; 95% CI −1.56 to 3.39; p = 0.47); oral semaglutide is under investigation in the ongoing phase II MOST-ABLE trial. In AD, the phase IIb liraglutide (ELAD) trial did not achieve statistical benefit on either its primary imaging endpoint (cerebral glucose metabolic rate; p = 0.14) or on most secondary cognitive measures, and the phase III semaglutide trials EVOKE and EVOKE+ did not meet their primary CDR-SB endpoint (estimated difference −0.08, 95% CI −0.35 to 0.20, p = 0.57 in EVOKE; 0.10, 95% CI −0.17 to 0.38, p = 0.46 in EVOKE+), despite biomarker signals including reductions in cerebrospinal fluid tau species and inflammatory markers. Comparative pharmacology reveals substantial heterogeneity in central nervous system penetration, receptor engagement, and systemic bioavailability across exenatide, liraglutide, semaglutide, and the imbalanced GLP-1/GIP co-agonist tirzepatide, complicating cross-agent extrapolation. Persistent challenges include separating direct neuroprotection from indirect metabolic and cardiovascular benefit, limited characterization of brain drug exposure, trial durations that may be short relative to the expected latency of a disease-modifying effect, and the absence of validated response biomarkers. We conclude that although the mechanistic and epidemiological rationale for GLP-1 RAs in neurodegeneration remains biologically plausible, current trial evidence does not yet support their use outside clinical trials, irrespective of comorbid diabetes status; future studies should prioritize earlier intervention, biomarker-guided patient selection, adequately powered subgroup analyses, and brain-penetrant formulations.

GLP-1 receptor agonistsParkinson's diseaseAlzheimer's diseasedisease-modifying therapy
مقالوصول مفتوح202510استشهاد· Semantic Scholar

Enhancing wearable sensor data analysis for patient health monitoring using allied data disparity technique and multi instance ensemble perceptron learning

Scientific Reports · مجلد 15 (1) · 29555-29555

Wearable Sensor (WS)-based monitoring systems detect minute patient movements/ demands and abnormalities through periodic sensing and imaging. Sensor data observed over different intervals is not constant or available based on operating sequences. Due to variations in data sequences, the analysis process becomes complex, resulting in less precise outputs. To address this problem, an Allied Data Disparity Technique (ADDT) is proposed in this article. This technique identifies the disparity in different monitoring sequences in coherence with the clinical and previous values. Based on the mean disparity, the data requirement for the WS sequence is decided. This decision uses multiple substituted and predicted values obtained from previous instances. Multi-Instance Ensemble Perceptron Learning is used in this decision process, where the substitution instances for clinical and previous outcomes are performed. The ensemble perceptron selects the maximum clinical value correlating sensor data to ensure high sequence prediction. The ensembles are updated based on the highest precision-based WS values for diagnosis. This diagnosis-focused coalition between clinical and predicted WS values is updated periodically for the new precision levels identified.

wearable sensorspatient health monitoringclinical data fusionmissing data imputation
مقالوصول مفتوح20228استشهاد· Semantic Scholar

Uncontrolled blood pressure among hypertensive adults with rheumatoid arthritis in Saudi Arabia

Medicine · مجلد 101 (4) · e28763-e28763

ABSTRACT: Despite the availability and advancement of diagnostic and treatments with demonstrated benefits in minimizing cardiovascular morbidity and mortality, hypertension control rates remain suboptimal. Therefore, this research aimed to determine the prevalence of uncontrolled BP in rheumatoid arthritis (RA) patients and understand all potential risk factors for uncontrolled BP.We conducted a cross-sectional study on RA patients in 2 rheumatology clinics in 2 public hospitals in Riyadh. Patients' information such as demographics, comorbidities, drug use, and other clinical data were captured through a review of medical records and supplemented by patient interviews. Multivariate logistic regression was utilized for the analysis to identify the significant factors of uncontrolled BP (systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg).In total, 834 subjects with RA and concomitant BP were involved in this cross-sectional study. The prevalence of uncontrolled BP was found to be 31.65% among all the study population. Multivariate analysis showed that males, subjects above 60 years of age, and smokers had a distinctly higher occurrence of uncontrolled BP. Among the patients with comorbid conditions, those with obesity, hyperlipidemia, diabetes, anemia, cancer, and reflex or gastroesophageal reflux disease also showed a significantly higher risk of uncontrolled BP (P < .05).The rate of uncontrolled BP was found to be alarmingly high in the study population. Age, gender, smoking, diabetes, obesity, hyperlipidemia, cancer, gastroesophageal reflux disease, and osteoporosis are independently linked with lack of BP control.

uncontrolled hypertensionhypertensionrheumatoid arthritisprevalence
مقالمفتوح (مستودع)20227استشهاد· Semantic Scholar

[Retracted] An ML‐Enabled Internet of Things Framework for Early Detection of Heart Disease

BioMed Research International · مجلد 2022 (1) · 3372296-3372296

Healthcare occupies a central role in sustainable societies and has an undeniable impact on the well-being of individuals. However, over the years, various diseases have adversely affected the growth and sustainability of these societies. Among them, heart disease is escalating rapidly in both economically settled and undeveloped nations and leads to fatalities around the globe. To reduce the death ratio caused by this disease, there is a need for a framework to continuously monitor a patient's heart status, essentially doing early detection and prediction of heart disease. This paper proposes a scalable Machine Learning (ML) and Internet of Things-(IoT-) based three-layer architecture to store and process a large amount of clinical data continuously, which is needed for the early detection and monitoring of heart disease. Layer 1 of the proposed framework is used to collect data from IoT wearable/implanted smart sensor nodes, which includes various physiological measures that have significant impact on the deterioration of heart status. Layer 2 stores and processes the patient data on a local web server using various ML classification algorithms. Finally, Layer 3 is used to store the critical data of patients on the cloud. The doctor and other caregivers can access the patient health conditions via an android application, provide services to the patient, and inhibit him/her from further damage. Various performance evaluation measures such as accuracy, sensitivity, specificity, F1-measure, MCC-score, and ROC curve are used to check the efficiency of our proposed IoT-based heart disease prediction framework. It is anticipated that this system will assist the healthcare sector and the doctors in diagnosing heart patients in the initial phases.

heart disease predictionearly detectionInternet of Thingswearable sensors
مقالوصول مفتوح202111استشهاد· Semantic Scholar

Identification of Gene Signature as Diagnostic and Prognostic Blood Biomarker for Early Hepatocellular Carcinoma Using Integrated Cross-Species Transcriptomic and Network Analyses

Frontiers in Genetics · مجلد 12 · 710049-710049

Background: Hepatocellular carcinoma (HCC) is considered the most common type of liver cancer and the fourth leading cause of cancer-related deaths in the world. Since the disease is usually diagnosed at advanced stages, it has poor prognosis. Therefore, reliable biomarkers are urgently needed for early diagnosis and prognostic assessment. Methods: We used genome-wide gene expression profiling datasets from human and rat early HCC (eHCC) samples to perform integrated genomic and network-based analyses, and discovered gene markers that are expressed in blood and conserved in both species. We then used independent gene expression profiling datasets for peripheral blood mononuclear cells (PBMCs) for eHCC patients and from The Cancer Genome Atlas (TCGA) database to estimate the diagnostic and prognostic performance of the identified gene signature. Furthermore, we performed functional enrichment, interaction networks and pathway analyses. Results: We identified 41 significant genes that are expressed in blood and conserved across species in eHCC. We used comprehensive clinical data from over 600 patients with HCC to verify the diagnostic and prognostic value of 41-gene-signature. We developed a prognostic model and a risk score using the 41-geneset that showed that a high prognostic index is linked to a worse disease outcome. Furthermore, our 41-gene signature predicted disease outcome independently of other clinical factors in multivariate regression analysis. Our data reveals a number of cancer-related pathways and hub genes, including EIF4E, H2AFX, CREB1, GSK3B, TGFBR1, and CCNA2, that may be essential for eHCC progression and confirm our gene signature’s ability to detect the disease in its early stages in patients’ biological fluids instead of invasive procedures and its prognostic potential. Conclusion: Our findings indicate that integrated cross-species genomic and network analysis may provide reliable markers that are associated with eHCC that may lead to better diagnosis, prognosis, and treatment options.

hepatocellular carcinomaearly diagnosisprognostic factorsblood biomarkers
مقالمفتوح (مستودع)20196استشهاد

Big Data Analytics for Value-Based Care: Challenges and Opportunities

International Journal of Advanced Trends in Computer Science and Engineering · مجلد 8 (6) · 3012-3016

Big data denotes large volume datasets that grows exponentially over time and cannot be processed or stored using traditional data management tools.There is a huge amount of new data that is stored daily in all areas of our life.This data needs to be collected and analyzed effectively to streamline the decision-making process.Big data analytics (BDA) are techniques that provide a way to analyze this huge quantity of data with the purpose of drawing conclusions about them by driving the business outcomes and real time decisions.With a wide range of data available in the healthcare sector including financial and clinical data, research and development, management and operational data and critical care units, big data in healthcare can generate meaningful insights to improve overall operational efficiency in the industry.There are various benefits for big data analytics in the health-care industry which encompasses advanced patient care; improved operational efficiency; evaluation of practitioner performance; reduced patient cost and researching cure for diseases.The main objective of this study is to outline the main challenges and opportunities of applying big data in health care and how it can help in transforming the healthcare industry towards the valuebased care.

big data analyticsvalue-based carebig data in healthcareclinical data
مقالوصول مفتوح20142استشهاد

Poor adherence to the World Health Organization guidelines of treatment of severe pneumonia in children at Khartoum, Sudan

BMC Research Notes · مجلد 7 (1) · 531-531

BACKGROUND: Community-acquired pneumonia (CAP) is as a major cause for childhood morbidity and mortality worldwide. This study was conducted to investigate the adherence and response of the WHO guidelines for treatment of severe pneumonia. METHOD: A cross-sectional study was conducted in the period of June 2009 to July 2010 at Khartoum Hospital, Sudan. Children admitted and treated for severe pneumonia were enrolled. RESULTS: Only 39 (18.8%) out of 208 enrolled children received prescriptions that were adherent to the WHO guidelines of treatment of severe pneumonia. In logistic regression none of the investigated variable (age, gender, and clinical presentations) was associated with the adherence to the WHO guidelines. There was no significant difference in the response between adherent and non-adherent prescriptions. There was no association between the demographic, clinical data, treatment-adherence to the guidelines and the patients' response. CONCLUSION: There is a poor (18.8%) adherence to the WHO guidelines of the treatment of severe pneumonia in the region regardless to the age, gender and clinical presentation.

severe pneumoniapediatric pneumoniaWHO treatment guidelinesguideline adherence